Sauter A et al. |
Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. |
2007 |
Int. J. Oncol. |
pmid:17332932
|
Chari RV et al. |
Immunoconjugates containing novel maytansinoids: promising anticancer drugs. |
1992 |
Cancer Res. |
pmid:1727373
|
Tan GT et al. |
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. |
1991 Jan-Feb |
J. Nat. Prod. |
pmid:1710653
|
Wenzel SC et al. |
On the biosynthetic origin of methoxymalonyl-acyl carrier protein, the substrate for incorporation of "glycolate" units into ansamitocin and soraphen A. |
2006 |
J. Am. Chem. Soc. |
pmid:17076505
|
Tijink BM et al. |
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. |
2006 |
Clin. Cancer Res. |
pmid:17062682
|
Kubota T et al. |
Determination of the cryptic stereochemistry of the first PKS chain-extension step in ansamitocin biosynthesis by Actinosynnema pretiosum. |
2006 |
Chembiochem |
pmid:16927319
|
Widdison WC et al. |
Semisynthetic maytansine analogues for the targeted treatment of cancer. |
2006 |
J. Med. Chem. |
pmid:16821799
|
Dymowski W and Furmanowa M |
[Investigating cytostatic substances in tissue of plants Maytenus Molina in in-vitro cultures. II. chromatographic test of extracts from callus of Maytenus wallichiana R. et B]. |
1990 |
Acta Pol Pharm |
pmid:1669332
|
Erickson HK et al. |
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. |
2006 |
Cancer Res. |
pmid:16618769
|
Kovtun YV et al. |
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. |
2006 |
Cancer Res. |
pmid:16540673
|